Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mechlorethamine
Drug ID BADD_D01359
Description A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
Indications and Usage For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
Marketing Status approved; investigational
ATC Code L01AA05
DrugBank ID DB00888
KEGG ID D07671
MeSH ID D008466
PubChem ID 4033
TTD Drug ID D03SSE
NDC Product Code Not Available
UNII 50D9XSG0VR
Synonyms Mechlorethamine | Chlormethine | Bis(2-chloroethyl)methylamine | Mustine | Nitrogen Mustard | Chlorethazine | Methylchlorethamine | Cloramin | Embichin | Mechlorethamine Hydrochloride | Hydrochloride, Mechlorethamine | Mechlorethamine Hydrochloride N-Oxide | Hydrochloride N-Oxide, Mechlorethamine | Mechlorethamine Hydrochloride N Oxide | N-Oxide, Mechlorethamine Hydrochloride | NSC-762 | NSC 762 | NSC762 | Mechlorethamine Oxide | Mitomen | Mustargen | Nitrogranulogen | Nitromin | NSC-10107 | NSC 10107 | NSC10107 | Caryolysine | Mechlorethamine N-Oxide | Mechlorethamine N Oxide | Nitrogen Mustard N-Oxide | N-Oxide, Nitrogen Mustard | Nitrogen Mustard N Oxide
Chemical Information
Molecular Formula C5H11Cl2N
CAS Registry Number 51-75-2
SMILES CN(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Inflammation10.02.01.089; 08.01.05.0070.000761%Not Available
Metastatic neoplasm16.16.01.0070.000112%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Disease progression08.01.03.0380.005787%
Pigmentation disorder23.05.03.0010.000571%Not Available
Sinus disorder22.04.06.0020.000246%
Unevaluable event08.01.03.0510.000627%Not Available
Skin haemorrhage23.06.07.001; 24.07.01.1030.000571%Not Available
Application site exfoliation23.03.07.007; 12.07.01.022; 08.02.01.0220.002474%Not Available
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.0380.002720%Not Available
Application site erosion23.07.03.011; 12.07.01.021; 08.02.01.0210.000627%Not Available
Application site scab23.03.03.050; 08.02.01.042; 12.07.01.0420.001142%Not Available
Skin sensitisation10.02.01.038; 23.03.03.0520.000381%Not Available
Application site haemorrhage24.07.01.048; 12.07.01.040; 08.02.01.0400.000951%Not Available
Skin texture abnormal23.03.03.0680.000571%Not Available
Application site bruise24.07.06.026; 23.03.11.026; 12.07.01.048; 08.02.01.0480.000381%Not Available
Application site fissure12.07.01.050; 08.02.01.0500.000381%Not Available
Application site wound12.07.01.056; 08.02.01.0560.000381%Not Available
Cutaneous T-cell lymphoma23.07.04.029; 16.17.03.002; 01.11.03.0020.001735%Not Available
Cutaneous T-cell lymphoma recurrent16.17.03.003; 01.11.03.003; 23.07.04.0300.000627%Not Available
Cutaneous T-cell lymphoma refractory23.07.04.031; 16.17.03.004; 01.11.03.0040.000112%Not Available
Symptom recurrence08.01.03.1010.000246%Not Available
Therapy non-responder08.06.01.0630.010443%Not Available
Therapy partial responder08.06.01.0640.000112%Not Available
Treatment noncompliance12.09.02.006; 08.06.01.0670.002586%Not Available
The 5th Page    First    Pre   5    Total 5 Pages